- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5%, Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL, SpyGlass IOL
- Drug · Device
- Lead sponsor
- SpyGlass Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Glendale, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 88
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle, Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Infantile Hemangioma
- Interventions
- Propranolol three times a day, Propranolol twice a day, Timolol
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- Up to 18 Months
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- Bimatoprost SR, Active Comparator: Timolol 0.5%, Sham: Applicator Without Needle, Timolol Vehicle (placebo)
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Glendale, California • Irvine, California + 51 more
- Conditions
- Glaucoma
- Interventions
- Timolol, latanoprost
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 36 Weeks to 18 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Pembroke Pines, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- OTX-TP, Timolol
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Scleral Buckling
- Interventions
- Timolol-dorzolamide (Glaucoma drops), standard post-operative topical drops
- Drug
- Lead sponsor
- Jason Hsu, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension
- Interventions
- Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3, Stage 1 - ATS907 - Dose 4, Stage 1 - Vehicle, Stage 2 - ATS907 - Dose A - to be selected based on Stage 1, Stage 2 - ATS907 - Dose B - to be selected based on Stage 1, Timoptic
- Drug
- Lead sponsor
- Altheos, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 5
- States / cities
- Artesia, California • Glendale, California • Saint Joseph, Michigan + 2 more
- Conditions
- Glaucoma
- Interventions
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, latanoprost 0.005%
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Slingerlands, New York
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo)
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 51
- States / cities
- Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more
- Conditions
- Infantile Hemangiomas
- Interventions
- Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Month to 8 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Ocular Hypertension, Open-angle Glaucoma
- Interventions
- AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- Up to 99 Years
- Enrollment
- 756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- 0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution, Brimonidine 0.2% ophthalmic solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- El Paso, Texas
- Conditions
- Glaucoma; Drugs
- Interventions
- CATS Tonometer, Latanoprost
- Device · Drug
- Lead sponsor
- Intuor Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Ocular Hypertension, Glaucoma
- Interventions
- latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5%
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1999
- U.S. locations
- 53
- States / cities
- Anaheim, California • Sacramento, California • San Francisco, California + 39 more
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- timolol maleate 0.5%, dorzolamide/timolol maleate fixed combination, latanoprost 0.005%, placebo
- Drug
- Lead sponsor
- Pharmaceutical Research Network
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 2
- States / cities
- Lakeland, Florida • Bourbonnais, Illinois
- Conditions
- Glaucoma, Open Angle, Ocular Hypertension
- Interventions
- Timolol Maleate in Sorbate, Timolol hemihydrate, Timolol maleate gel forming solution
- Drug
- Lead sponsor
- Vistakon Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 2
- States / cities
- Bourbonnais, Illinois • Charlotte, North Carolina
- Conditions
- Mohs Micrographic Surgery, Excision Margin
- Interventions
- Timolol 0.5% Ophthalmic Solution, Hydrogel of placebo
- Drug · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Sacramento, California
- Conditions
- Glaucoma
- Interventions
- Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%
- Drug
- Lead sponsor
- Innovative Medical
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Migraine
- Interventions
- Timolol, Placebo
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- AL-37807 ophthalmic suspension, 0.1%, Timolol gel forming solution, 0.5%, AL-37807 ophthalmic solution vehicle, Latanoprost ophthalmic solution
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas